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Abstract (250 words) 
Background 
In the HypoCOMPaSS trial, adults with long-standing type 1 diabetes and problematic hypoglycaemia 
were randomised to compare insulin pump (CSII) vs multiple daily injections (MDI) and real-time 
continuous glucose monitoring (RT-CGM) vs conventional self-monitoring (SMBG). Our aim was to 
investigate participants’ satisfaction with these technologies at 6-month RCT endpoint and at 2-year 
follow-up.  
Methods 
Participants completed the Insulin Treatment Satisfaction Questionnaire (ITSQ) subscales ‘device 
delivery’ and ‘hypoglycaemia control’; and Glucose Monitoring Experience Questionnaire (GME-Q), 
assessing ‘convenience’, ‘effectiveness’, ‘intrusiveness’ and ‘total satisfaction’. We assessed change 
over time and between group differences by insulin and monitoring modalities. 
Results 
Participants (N=96) were: 64% women, aged 49±12 years, diabetes duration 29±12 years. At 6 
months, participants reported improvements compared to baseline (all p<0.001) in satisfaction with 
insulin ‘delivery device’ (r=0.39) and ‘hypoglycaemia control’ (r=0.52), and trends towards 
significance in perceived ‘effectiveness’ (r=0.42) and ‘intrusiveness’ (r=0.27) of monitoring device 
(but not ‘convenience’, p=0.139). All improvements were sustained at 2 years. At 6 months, the only 
difference between arms was that greater satisfaction with insulin ‘delivery device’ was reported in the 
CSII group compared to MDI (p<0.001, r=0.40). No between-group differences were observed at 2 
years.    
Conclusions 
Overall, significant improvements in participant satisfaction with diabetes technologies were observed 
over the 6-month RCT, in all domains except ‘convenience’, maintained at 2 years. While 
HypoCOMPaSS demonstrated non-inferiority of SMBG versus CGM, and MDI versus CSII in terms 
of biomedical outcomes, detailed assessments confirm participants satisfaction with delivery device 
was greater in those allocated to CSII than MDI. 
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Introduction 
Despite advances in diabetes care, problematic hypoglycaemia continues to impose a major burden on 
people with type 1 diabetes and remains one of its most feared complications.1 Previously, the 
HypoCOMPaSS randomised controlled trial (RCT) demonstrated that it is possible to improve 
awareness of hypoglycaemic symptoms and prevent recurrent severe hypoglycaemia in a high-risk 
population of adults with long-standing type 1 diabetes without relaxing HbA1c targets.2 Furthermore, 
after the initial 6-month RCT, these benefits were sustained for a further eighteen months.3 The 
HypoCOMPaSS RCT compared insulin pumps (CSII) with multiple daily injections (MDI) and 
adjuvant real-time continuous glucose monitoring (RT-CGM) with conventional self-monitoring of 
blood glucose (SMBG) for the first time in adults with type 1 diabetes who had demonstrable 
hypoglycaemia unawareness and/or a history of recurrent severe hypoglycaemia. Moreover, 
participants received equivalent education, clinical support and attention regardless of their trial 
allocation.4 The observed improvements in hypoglycaemia awareness and severe hypoglycaemia rates 
were equivalent across insulin delivery and glucose monitoring modalities, highlighting the pivotal 
roles of insulin titration, brief psycho-educational training and intensive clinical support.2  
 
We have reported previously that treatment satisfaction was improved in all trial arms (CSII vs. MDI; 
RT-CGM vs. SMBG) from baseline to 6-month RCT endpoint.2 Furthermore, those randomised to 
CSII reported greater satisfaction at 6 months than those using MDI, while no difference was observed 
between those allocated to RT-CGM and SMBG.2 Satisfaction was assessed using the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ),5 which is a brief, validated and widely used measure, 
designed to provide a ‘total satisfaction’ score incorporating all aspects of diabetes treatment 
“including insulin, tablets and/or diet”. However, depending on the respondent’s interpretation of 
‘treatment’, their score may or may not reflect their satisfaction with glucose monitoring. Further, a 
brief ‘all purpose’ assessment, designed to be suitable for all types of diabetes treatment, may not fully 
capture satisfaction with insulin treatment, as it does not consider specific features of, and experiences 
with, insulin delivery devices. Various scales have been developed to overcome these potential 
limitations.6, 7  
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The HypoCOMPaSS study offers a unique opportunity to provide a detailed assessment of satisfaction 
with insulin delivery and glucose monitoring devices in adults with type 1 diabetes and problematic 
hypoglycaemia. Thus, the aims of the current study were to use additional patient-reported outcome 
measures (PROMs) to examine specifically: a) satisfaction with insulin delivery modality and 
perceived glucose monitoring experience at the conclusion of the 6-month trial; b) whether satisfaction 
at 6 months differ by device allocation (CSII vs. MDI; RT-CGM vs. SMBG); c) these outcomes at 2-
year follow-up overall, and by device allocation; d) these outcomes at 2-year follow-up using per 
protocol analysis for insulin delivery and glucose monitoring device use. 
Methods 
Study design  
The HypoCOMPaSS study protocol and findings have been reported elsewhere.2-4 In brief, 
HypoCOMPaSS was a multi-centre trial (including 5 UK tertiary referral diabetes centres), over a 6-
month period, with a 2x2 factorial design. The overall aim was to investigate whether impaired 
awareness of hypoglycaemia could be improved, and recurrent severe hypoglycaemia prevented. Prior 
to randomisation, all participants attended a single, brief (1-2 hour) structured psycho-educational 
program (‘My HypoCOMPaSS’) focused on hypoglycaemia avoidance, delivered individually or in 
small groups of up to four participants.2 Participants were then randomised to one of four groups 
comparing two insulin delivery modalities (CSII vs. MDI) in combination with two glucose 
monitoring modalities (RT-CGM vs. SMBG). All participants received equivalent intensive clinical 
support, including 4-weekly follow-up visits, throughout the RCT.  
 
All participants were given an insulin pump that could receive and display CGM data (Paradigm Veo; 
Medtronic) as well as receive data transmitted from their SMBG meter at the time of each ‘finger 
prick’ blood glucose check. All were taught how to use the on-board bolus calculator. Only those 
randomised to CSII used the insulin pump for insulin aspart administration, while those allocated to 
MDI only used the bolus calculator and, if allocated to RT-CGM, the CGM feature. Those allocated to 
CSII were given a single additional session restricted to technical aspects of pump management. Those 
allocated to MDI administered insulin aspart and glargine using 3ml cartridges 100 Units/mL in pre-
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filled pens (Flexpen® and Solostar® respectively).  All participants were given a Contour link® meter 
(Bayer Healthcare) and required to undertake daily 4-point and weekly 8-point self-monitored 
capillary glucose profiles. In addition, those allocated to RT-CGM were provided with sensors for 
uninterrupted use of the CE-marked REAL-time monitor (Medtronic) and given a single additional 
session restricted to technical aspects of RT-CGM. At the conclusion of the 6-month RCT, 
participants had the option of switching their insulin delivery modality. Access to RT-CGM sensors 
continued beyond the RCT for those randomised to the RT-CGM. 
 
Ethical approval was obtained from a central Research Ethics Committee and the Medicines and 
Healthcare products Regulatory Agency, with independently-chaired Trial Steering Committee and 
Data Monitoring and Ethics Committee oversight. Informed consent was obtained from all 
participants. For the purposes of secondary data analyses, ethics approval was subsequently granted by 
Deakin University Human Research Ethics Committee (2016-011). 
Participants  
Eligible participants were adults (aged 18-74 years) with type 1 diabetes and impaired awareness of 
hypoglycaemia and no prior experience with RT-CGM.  As described in full elsewhere,2, 4 96 
participants were randomised: 50 (52%) participants were randomised to MDI, with the remaining 
randomised to CSII (n=46, 48%). Half of the sample (n=48) were randomised to either SMBG or RT-
CGM. At the conclusion of the 6-month RCT, participants had the option of switching their insulin 
delivery modality. At 2 years, 20 (21%) participants were lost to follow-up. Baseline characteristics 
were similar across those retained and lost.2 Half of participants (n=41) had switched insulin delivery 
modality, with use of both MDI and CSII during the 2-year study.3 Access to RT-CGM sensors 
continued beyond the RCT for those randomised to the RT-CGM, with 11 (30%) participants using 
RT-CGM throughout the 18-month follow-up period.  
Measures 
All outcome measures have been described in the study protocol,4 and primary outcomes of the 6-
month RCT and 2-year follow-up have been reported previously.2, 3 The current study examines data 
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collected from the following patient-report outcome measures completed at baseline, 6 months (RCT 
endpoint), and 2 years (study endpoint). 
  
Satisfaction with insulin delivery device was assessed with two subscales of the Insulin Treatment 
Satisfaction Questionnaire (ITSQ): ‘hypoglycaemia control’ (5 items) and ‘device delivery’ 
satisfaction (6 items).7 Other subscales were excluded as they were deemed not relevant to the aims of 
the HypoCOMPaSS study. Participants respond to questions about their insulin treatment on a 7-point 
scale (1-7). Subscale scores are calculated by summing reversed item scores and standardizing as a 
score out of 100, where higher scores indicate greater satisfaction. The ITSQ was designed and 
validated for use across insulin administration types, including manual injections and insulin pump 
therapy.7  
 
Satisfaction with glucose monitoring device was assessed using the 22-item Glucose Monitoring 
Experience Questionnaire (GME-Q).6 Participants indicate their level of agreement (1=‘strongly 
disagree’ to 5= ‘strongly agree’) with 22 statements about their current monitoring device. Monitoring 
experience is assessed across three domains: ‘effectiveness’ (9 items), ‘intrusiveness (6 items)’, 
‘convenience’ (7 items). Within each domain, item scores are summed and divided by the number of 
items resulting in a composite score (range=1-5), with higher scores indicating greater experience of 
that domain. A GME-Q composite score (‘total satisfaction’) can also be calculated, where higher 
scores indicate more positive overall experience of (greater satisfaction with) their monitoring device. 
For the ‘effectiveness’ and ‘convenience’ domain scores, and the ‘total satisfaction’ score, negatively 
worded items are reversed before scoring. The GME-Q was designed to be applicable for both SMBG 
and CGM users.6  
 
In addition, the following variables were analysed: RCT arm allocation (MDI vs CSII; SMBG vs RT-
CGM); change in insulin device delivery and use of RT-CGM (<50 versus ≥50% of days in study) 
following the 6-month RCT; other demographic and clinical characteristics.  
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Statistical analysis  
Statistical analysis was undertaken using SPSS Version 24 (Chicago, USA). Missing data were not 
imputed, and participants with missing ITSQ and GME-Q scores were excluded from analysis as 
relevant. Scale distributions were graphed and inspected to check for normality. All scales scores had 
non-normal distributions and, consequently, non-parametric tests were conducted. Descriptive 
statistics (median [interquartile range], or n, %) are reported for ITSQ and GME-Q domain scores 
across all time points (baseline to 2 years). Due to the incomplete data across all time points, and the 
subsequent pair-wise deletion in analysis, repeated measures Wilcoxon-signed-rank tests were 
conducted first to explore change in ITSQ and GME-Q subscales from baseline to 6 months, followed 
by repeated measures Freidman’s analysis of variance (ANOVA) to compare change from baseline, to 
6 months and 2 years. Mann-Whitney tests were conducted to assess between-group differences in 
ITSQ scores (MDI vs. CSII) and GME-Q scores (RT-CGM vs. SMBG) at 6 months and 2 years. As 
participants had the freedom to change their insulin delivery modality following the RCT, at 2 years, 
ITSQ descriptive statistics were examined comparing three scenarios: those who used MDI only 
throughout, those switched (with use of both MDI and CSII) during the 2 years, and CSII only 
throughout. Among participants with complete RT-CGM usage data at 2 years, GME-Q descriptive 
statistics were inspected for those who used RT-CGM for <50% vs. ≥50% of the time but statistical 
analysis was deemed inappropriate given the small samples included in per protocol groups. All 
statistical tests were two-sided and, given these are secondary analyses, differences were accepted as 
significant at a conservative p<0.001. Effect sizes are reported as r; interpretation coincides with that 
used for Pearson’s correlation coefficient (r). 
Results 
Participant characteristics 
As reported elsewhere,2 the RCT participants were 96 adults with long-standing type 1 diabetes 
(diabetes duration: 29±12 years), aged 49±12 years. Sixty-one (64%) were women. Ninety-three 
(97%) were using MDI and three (3%) CSII prior to randomisation. Demographic characteristics of 
the 76 (79%) participants retained at 2-year study follow-up were comparable with the RCT sample, 
and retention was consistent across study arms (between 77% and 81%).3  
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6-month RCT 
Table 1 displays median [lower, upper inter quartile] ITSQ and GME-Q scores for the whole sample 
across all time-points. Comparing baseline to the 6-month endpoint of the RCT (using pair-wise 
deletion), participants reported significant improvements in their satisfaction with insulin ‘delivery 
device’ (median diff=8.3[0,27.8], T=2452, p<.001, r=0.39) and ‘hypoglycaemia control’ (median 
diff=23.3[5.0,40.0], T=2793,p<.001, r=0.52). Similarly, participants reported significant 
improvements in their ‘total satisfaction’ with their monitoring device (median diff=0.22[0.0,0.5], 
T=2550, p<.001, r=0.40). Specifically, participants’ reports of the perceived ‘effectiveness’ of their 
monitoring device increased (median diff=0.3[0.0,0.9], T=2333, p<.001, r=0.42), while ‘intrusiveness’ 
reduced (median diff=-0.2 [-0.5,0.2], T=595, p<.001, r=0.27). There was no change in perceived 
‘convenience’ (median diff=0.14[-0.3,0.4], T=1518.5, p=0.105).  
 
Table 2 displays median [lower, upper inter quartile] ITSQ and GME-Q scores by study allocation at 
6-month RCT endpoint and 2-year study endpoint (ITT). At the 6-month RCT endpoint, participants 
randomised to CSII reported greater satisfaction with their insulin ‘device delivery’ (U=1250, z=3.6, 
p<.001, r=0.40) than those allocated to MDI, and there was a trend towards greater satisfaction with 
‘hypoglycaemic control’ (U=1049, z=2.0, p=.043, r=0.22). GME-Q ‘total satisfaction’ and domain 
scores were similar at 6 months between those allocated to RT-CGM and those allocated to SMBG 
alone. Those randomised to RT-CGM perceived a trend toward greater ‘effectiveness’ of their 
monitoring device than those allocated to SMBG (U=1090, z=2.10, p=0.036, r=0.23).  
2-year study 
For the whole sample, comparing baseline, 6-month RCT endpoint and 2-year study endpoint, 
significant improvements were observed in satisfaction with insulin ‘delivery device’ (ꭓ2(2)=26.0, 
p<.001) and ‘hypoglycaemic control’ (ꭓ2(2)=36.4, p<.001). A trend towards significant improvements 
was observed for perceived ‘effectiveness’ (ꭓ2(2)=13.4, p=.001) and ‘intrusiveness’ of (ꭓ2(2)=6.9, 
p=.032), and ‘total satisfaction’ (ꭓ2(2)=12.0, p=.002) with, their glucose monitoring device. There was 
no significant change in perceived ‘convenience’ of glucose monitoring device across time points for 
the whole sample (ꭓ2(2)=5.3, p=0.071).  
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Post-hoc comparisons revealed no significant change from RCT endpoint to 2-year study endpoint in 
any of the ITSQ or GME-Q scores, suggesting that satisfaction stabilised post 6 months. However, 
there was a non-significant trend towards increased satisfaction with insulin ‘delivery device’ 
following conclusion of the RCT (Table 1). 
  
At the 2-year study endpoint, no significant between-group differences were observed in ITSQ 
subscale scores by insulin delivery group, or in GME-Q scores by glucose monitoring group (ITT) 
(Table 2). Following the RCT endpoint, descriptive statistics suggest that those who continued to use 
CSII, and those who switched their insulin delivery modality, reported greater satisfaction with their 
insulin ‘device delivery’ at 2 years compared to those who remained on MDI, while satisfaction with 
‘hypoglycaemia control’ did not vary by insulin modality. Although numbers were low, participants 
with greater use of RT-CGM (≥50% vs <50%) perceived their monitoring method to be more 
convenient and effective, and less intrusiveness at 2 years (Table 3). 
Discussion 
Previous reports from the HypoCOMPaSS study described non-inferiority (of MDI versus CSII and 
SMBG versus RT-CGM) in terms of biomedical outcomes in adults with longstanding type 1 diabetes 
and problematic hypoglycaemia, and significantly improved satisfaction overall, but particularly for 
those allocated to CSII.2, 3 The current study’s more detailed assessments of participants’ experiences 
with these diabetes technologies (using the ITSQ and GME-Q) confirms significant improvement over 
6 months in several aspects of satisfaction for both insulin delivery and glucose monitoring devices. It 
confirms that participants were more satisfied with CSII than MDI, aspreviously shown with DTSQ,2, 3 
and that these improvements were maintained at 2 years. In addition, while data are limited, the 2-year 
per protocol analysis suggests that, when given their preference of insulin delivery and glucose 
monitoring device at the end of the 6-month RCT, there were no significant differences in ITSQ scores 
for those remaining on MDI or CSII or switching, i.e. everyone was equally satisfied with their choice. 
Finally, those who used RT-CGM more than half of the time throughout follow-up had the greatest 
satisfaction levels.  
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Systematic reviews and meta-analyses show there have been few RCTs that have examined 
satisfaction with advanced diabetes technologies compared with conventional modalities, with mixed 
findings for CSII compared with MDI, with no difference shown for RT-CGM compared with 
SMBG.8, 9 However, prior to HypoCOMPaSS, none of the RCTs had been conducted in a high-risk 
group of adults with long-standing type 1 diabetes and problematic hypoglycaemia; indeed, it has 
usually been the case that those with impaired awareness and/or history of severe hypoglycaemia have 
been excluded from such studies. Further, HypoCOMPaSS is one of the few studies to compare such 
technologies while ensuring equal attention to education, clinical support and attention – the notable 
exception being the REPOSE trial, which compared MDI and CSII after structured type 1 diabetes 
education.10 Similarly, REPOSE found biomedical non-inferiority of MDI compared with CSII and 
that treatment satisfaction was greater among those allocated to CSII. 
 
Valid and reliable measurement of the experience of the person with diabetes is fundamental to 
improving the quality of diabetes care. While biomedical outcomes can tell us whether interventions 
are working, we will only know if they are working well enough, and likely to produce sustainable 
outcomes, if we ask the people who need to use them in their everyday lives. This study expanded 
upon our previous HypoCOMPaSS findings by examining responses to two detailed measures of 
diabetes treatment satisfaction, one focused on issues related specifically to insulin delivery (ITSQ) 
and one on glucose monitoring (GME-Q). Many previous trials of insulin delivery and glucose 
monitoring technologies have incorporated only brief and broad measures of diabetes treatment 
satisfaction.11, 12 Brief measures offer a significant advantage in terms of low respondent burden but 
can be limited by not enabling the respondent to fully consider various specific aspects of their 
experience, and consequently, both respondent and researcher interpretation may be questionable. For 
example, the DTSQ instructions and questions do not readily highlight that glucose monitoring is part 
of the diabetes treatment experience. The current findings highlight that those allocated to CSII were 
more satisfied with their insulin delivery device than those allocated to MDI, with no significant 
differences in satisfaction with hypoglycaemic control, or in terms of other aspects of satisfaction 
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between those allocated to SMBG and RT-CGM. The DTSQ has shown differences between diabetes 
technologies in other randomised studies.11, 13 Our discrepant finding may be explained by the fact that 
the design of HypoCOMPaSS ensured that all participants (regardless of treatment allocation) 
received equal education, clinical support and attention with particular focus on optimising the utility 
and potential benefits of MDI and SMBG, through direct linking of data to a bolus wizard and targeted 
testing including nocturnally to identify times of risk and inform proactive steps towards prevention 
and minimisation of significant hypoglycaemia.  Regardless, it is clear that measures beyond DTSQ 
should be considered in future studies of advanced glucose monitoring technologies for valid 
assessment of the user’s experience.  
 
This study also has some limitations. It is not possible to conceal insulin delivery and glucose 
monitoring device allocations from study participants or clinicians when their features and capabilities 
are so different. While some biomedical outcomes are objective markers (e.g. HbA1c) and not subject 
to self-report bias, treatment satisfaction is necessarily a subjective, patient-reported outcome, and this 
could be considered problematic. Further, the concept of satisfaction can be criticised as being subject 
to factors such as ‘gratitude bias’ (i.e. participants feeling indebted for the opportunity to access the 
latest treatments), but it is also recognised that people want to provide valid responses reflecting the 
gap between their expectations and their experiences in order to improve healthcare.14 Importantly, we 
used valid and reliable measures of satisfaction6, 7 and have discussed these findings in relation to 
those of the DTSQ,2, 3, 5 arguably the most widely-used brief measure of diabetes treatment 
satisfaction.  
 
Another limitation is that uninterrupted RT-CGM was not achieved. Participants were trained in 
sensor insertion, calibration, and use of monitors (including trend analysis, individualizing alarm 
settings and low-glucose alerts) but did not use the low-glucose suspend feature. The fact that 
uninterrupted RT-CGM use was not realised may reflect the fact that the study used an early iteration 
of CGM technology, and problems with sensors, calibration etc are well-documented.15 It may also 
reflect real-world use, whereby people with diabetes do not perceive the need for uninterrupted use in 
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order to experience benefits and/or that uninterrupted use represented an added burden to diabetes 
self-care.16 It is also the case that HypoCOMPaSS took a very pro-active approach regarding SMBG, 
as evidenced by the equivalent satisfaction with this modality. Education was targeted to optimising 
the use of SMBG to increase awareness and understanding of times of risk for hypoglycaemia, 
increasing ability to detect, and confidence to respond safely and effectively, to glucose levels. 
Further, while a 95% reduction in severe hypoglycaemia rate was achieved over the 2-year study 
without activation of the low-glucose suspend feature, we acknowledge that greater satisfaction could 
have been achieved if the potential benefits of automated suspension of insulin delivery had been 
realised during HypoCOMPaSS.3 
 
The HypoCOMPaSS study has several clinical and research implications, which have been reported 
previously.2, 3 The use of more detailed assessments in the current study confirms that most aspects of 
satisfaction improved significantly at 6 months (overall, regardless of trial allocation) – including 
insulin ‘delivery device’ and ‘hypoglycaemia control’, and glucose monitoring ‘total satisfaction’, 
‘effectiveness’ and ‘intrusiveness’ but not ‘convenience’ – and were maintained at 2 years, mirroring 
improvements in biomedical outcomes. This highlights the importance of ensuring equivalent 
education, clinical support and attention throughout the 6-month RCT and their continued benefits for 
maintaining biomedical outcomes and satisfaction at the 2-year study endpoint. These findings support 
current evidence-informed and cost-effective clinical practice recommendations,17 in which insulin 
titration, structured education and intensive clinical support can be offered to all before introducing 
advanced diabetes technologies, in the anticipation that most will benefit in terms of both biomedical 
and psychological outcomes. The findings in relation to satisfaction with glucose monitoring highlight 
the limitations of the technology used in the HypoCOMPaSS trial as well as the burden of intensive 
monitoring. Given that technologies are advancing at a rapid pace, close attention needs to be paid to 
the users’ experience (in clinical practice and research) using validated measures. When planning 
future diabetes technology trials, we suggest adoption of the approach used in the HypoCOMPaSS and 
REPOSE trials (i.e. ensuring equivalent education, clinical support and attention to all groups) and 
thus isolating the effect of the technology from any confounders. 
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In conclusion, the use of the ITSQ and GME-Q measures enabled detailed characterization of the 
experience of using insulin delivery and glucose monitoring devices. Significant improvements were 
observed over the 6-month RCT in satisfaction with insulin delivery and glucose monitoring 
technologies, in all domains except ‘convenience’, and these were maintained at 2 years. While 
HypoCOMPaSS demonstrated non-inferiority of SMBG versus CGM, and MDI versus CSII in terms 
of biomedical outcomes, detailed satisfaction assessments confirm participants were more satisfied 
with CSII than MDI in terms of insulin delivery device. Future trials of glucose monitoring devices 
would benefit from inclusion of monitoring-specific satisfaction measures in order to meaningfully 
determine participant experiences. 
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Table 1. ITSQ and GME-Q scores for the whole sample at all study time-points  
 
Baseline 
6 months 
(RCT endpoint) 
2 years 
(Study endpoint) 
ITSQ    
Delivery Device 
70.8 [53.5,83.3] 
 (n=96) 
83.3 [69.4,86.7] 
(n=82) 
91.7 [83.3,97.2] 
(n=56) 
Hypoglycaemic Control 
43.3 [30.0,56.7] 
(n=94) 
70.0 [59.2,84.2] 
(n=83) 
70.0 [60.0,97.2] 
(n=55) 
GME-Q 
Convenience 
 
3.7 [3.3,4.1] 
(n=95) 
4.0 [3.3,4.3] 
(n=82) 
3.9 [3.4,4.3] 
(n=54) 
Effectiveness 
 
3.6 [3.0,3.9] 
(n=95) 
3.9 [3.7,4.2] 
(n=83) 
3.9 [3.5,4.1] 
(n=53) 
Intrusiveness 
2.5 [2.0,2.9] 
(n=94) 
2.3 [2.0,2.8] 
(n=82) 
2.2 [1.5,2.7] 
(n=54) 
Total Satisfaction 
3.6 [3.2,3.8] 
(n=94) 
3.8 [3.4,4.1] 
(n=80) 
3.9 [3.5,4.3] 
(n=53) 
Data are median [lower, upper quartile]. Number of participants with available data is denoted by (n).   
GME-Q = Glucose Monitoring Experience Questionnaire, ITSQ = Insulin Treatment Satisfaction Questionnaire. 
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Table 2. ITSQ and GME-Q scores by study arm allocation at 6-month RCT endpoint and 2-year study endpoint (ITT)  
ITSQ Endpoint MDI CSII P-value 
Delivery Device 
RCT: 6 months 75.0 [61.1,94.4] (n=45) 94.4 [83.3,100] (n=38) <.001 
Study: 2 years 87.5 [87.5,94.4] (n=28) 94.4 [84.0,99.4] (n=28) 0.203 
Hypoglycaemic Control 
RCT: 6 months 63.3 [63.3,80.0] (n=45) 76.7[63.3,88.3] (n=37) 0.043 
Study: 2 years 70.0 [53.3,80.0] (n=28) 70.0[63.3,83.3] (n=27) 0.691 
GME-Q Endpoint SMBG RT-CGM  
Convenience 
RCT: 6 months 3.7 [3.3,4.2] (n=41) 3.7 [3.1,4.3] (n=41) 0.639 
Study: 2 years 4.0 [3.6,4.25] (n=28) 3.8 [3.4,4.3] (n=26) 0.549 
Effectiveness 
RCT: 6 months 3.8 [3.4,4.1] (n=41) 4.0 [3.7,4.4] (n=42) 0.036 
Study: 2 years 3.9 [3.3,4.0] (n=28) 4.0 [3.6,4.3] (n=25) 0.126 
Intrusiveness 
RCT: 6 months 2.3 [2.0,3.0] (n=40) 2.2 [1.8,1.7] (n=42) 0.396 
Study: 2 years 2.2 [1.7,2.5] (n=28) 2.3 [1.3,2.8] (n=26) 0.775 
Total Satisfaction 
RCT: 6 months 3.7 [3.3,4.0] (n=40) 3.7 [3.5,4.2] (n=40) 0.528 
Study: 2 years 3.8 [3.5,4.0] (n=28) 3.9 [3.4,4.4] (n=25) 0.649 
Data are median [lower, upper quartiles]. Number of participants with available data denoted by (n).  
P-values compare groups using independent-samples t-tests.  
GME-Q = Glucose Monitoring Experience Questionnaire, ITSQ = Insulin Treatment Satisfaction Questionnaire.  
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Table 3. ITSQ and GME-Q scores at 2-year endpoint (per protocol): insulin delivery modality (MDI only vs. CSII only vs. switched) 
and RT-CGM use (<50% vs. ≥50% use) 
ITSQ 
Insulin delivery modality throughout 2-year study 
MDI only 
Switched  
(MDI & CSII) 
CSII only 
Delivery Device 
80.6[72.2,86.1] 
(n=7) 
93.1 [79.2,100] 
(n=28) 
94.4 [86.1,97.2] 
(n=18) 
Hypoglycaemic Control 
70.0 [66.7,80.0] 
(n=7) 
73.3 [55.0,82.5] (n=28) 
71.7 [62.5,84.2] 
(n=18) 
GME-Q 
RT-CGM use  
< 50% ≥50%  
Convenience 
3.7[3.2,4.0] 
(n=5) 
4.1 [2.9,4.8] 
(n=6) 
 
Effectiveness 
3.7 [3.4,4.4] 
(n=5) 
4.2 [3.6,4.5] 
(n=6) 
 
Intrusiveness 
2.7 [1.9,2.9] 
(n=5) 
1.5 [1.3,3.2] 
(n=6) 
 
Total Satisfaction 
3.6 [3.3,4.2] 
(n=5) 
4.3 [3.2,4.6] 
(n=6) 
 
Data are median [lower, upper quartile]. Number of participants with available data denoted by (n). 
GME-Q = Glucose Monitoring Experience Questionnaire, ITSQ = Insulin Treatment Satisfaction Questionnaire.  
 
 
 
